Literature DB >> 19774327

Hotlines and clinical trial updates presented at the European Society of Cardiology Meeting 2009: data from RE-LY, PLATO, MADIT-CRT, PROTECT, SYNTAX, TRITON and more.

S H Schirmer1, A M van der Laan, M Böhm, F Mahfoud.   

Abstract

This summary article provides an update on novel clinical trials in the field of cardiovascular (CV) medicine which were presented at the annual meeting of the European Cardiac Society, held in Barcelona, Spain, in August-September 2009. The data were presented by leading experts in the field with relevant positions in the trials and registries. Unpublished reports should be considered as preliminary data as the analysis may change in the final publications. This article provides the reader with comprehensive summaries of the most recent diagnostic and therapeutic developments in CV medicine as previously reported (Kindermann et al. in Clin Res Cardiol 96:767-786, 2007; Müller et al. in Clin Res Cardiol 97:851-864, 2008).

Mesh：

Year:  2009        PMID： 19774327     DOI： 10.1007/s00392-009-0085-2

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN： 1861-0684            Impact factor:   5.460


  29 in total

1.  Highlights of the hotline sessions presented at the scientific sessions 2008 of the American Heart Association.

Authors:  Helge Möllmann; Holger Nef; Michael Böhm; Ulrich Laufs
Journal:  Clin Res Cardiol       Date:  2008-12-12       Impact factor: 5.460

2.  The basic pacing rate in CRT patients: the higher the better?

Authors:  Frederik Voss; Ruediger Becker; Melanie Hauck; Hugo A Katus; Alexander Bauer
Journal:  Clin Res Cardiol       Date:  2009-02-13       Impact factor: 5.460

3.  Routine invasive strategy within 24 hours of thrombolysis versus ischaemia-guided conservative approach for acute myocardial infarction with ST-segment elevation (GRACIA-1): a randomised controlled trial.

Authors:  Francisco Fernandez-Avilés; Joaquín J Alonso; Alfonso Castro-Beiras; Nicolás Vázquez; Jesús Blanco; Juan Alonso-Briales; Juan López-Mesa; Felipe Fernández-Vazquez; Isabel Calvo; Luis Martínez-Elbal; José A San Román; Benigo Ramos
Journal:  Lancet       Date:  2004 Sep 18-24       Impact factor: 79.321

4.  Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial.

Authors:  Marc S Sabatine; Elliott M Antman; Petr Widimsky; Iftikhar O Ebrahim; Robert G Kiss; André Saaiman; Rostislav Polasek; Charles F Contant; Carolyn H McCabe; Eugene Braunwald
Journal:  Lancet       Date:  2009-08-28       Impact factor: 79.321

5.  Differential associations between renal function and "modifiable" risk factors in patients with chronic heart failure.

Authors:  Tom D J Smilde; Kevin Damman; Pim van der Harst; Gerjan Navis; B Daan Westenbrink; Adriaan A Voors; Frans Boomsma; Dirk J van Veldhuisen; Hans L Hillege
Journal:  Clin Res Cardiol       Date:  2008-10-31       Impact factor: 5.460

6.  Efficacy and safety of immediate angioplasty versus ischemia-guided management after thrombolysis in acute myocardial infarction in areas with very long transfer distances results of the NORDISTEMI (NORwegian study on DIstrict treatment of ST-elevation myocardial infarction).

Authors:  Ellen Bøhmer; Pavel Hoffmann; Michael Abdelnoor; Harald Arnesen; Sigrun Halvorsen
Journal:  J Am Coll Cardiol       Date:  2009-09-10       Impact factor: 24.094

7.  Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.

Authors:  Kim Fox; Ian Ford; P Gabriel Steg; Michal Tendera; Roberto Ferrari
Journal:  Lancet       Date:  2008-08-29       Impact factor: 79.321

8.  Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome.

Authors:  P Michael Ho; Thomas M Maddox; Li Wang; Stephan D Fihn; Robert L Jesse; Eric D Peterson; John S Rumsfeld
Journal:  JAMA       Date:  2009-03-04       Impact factor: 56.272

9.  Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial.

Authors:  Kim Fox; Ian Ford; Ph Gabriel Steg; Michal Tendera; Michele Robertson; Roberto Ferrari
Journal:  Eur Heart J       Date:  2009-08-31       Impact factor: 29.983

10.  Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.

Authors:  Colin Baigent; Lisa Blackwell; Rory Collins; Jonathan Emberson; Jon Godwin; Richard Peto; Julie Buring; Charles Hennekens; Patricia Kearney; Tom Meade; Carlo Patrono; Maria Carla Roncaglioni; Alberto Zanchetti
Journal:  Lancet       Date:  2009-05-30       Impact factor: 79.321
View more
  3 in total

Review 1.  Hotline sessions and clinical trial updates presented at the European Society of Cardiology Congress in Stockholm 2010.

Authors:  Matthias Lenski; Felix Mahfoud; Christian Werner; Axel Bauer; Michael Böhm
Journal:  Clin Res Cardiol       Date:  2010-10-02       Impact factor: 5.460

Review 2.  Hot topics in cardiology: data from IABP-SHOCK II, TRILOGY-ACS, WOEST, ALTIDUDE, FAME II and more.

Authors:  Christian Ukena; Michael Böhm; Stephan H Schirmer
Journal:  Clin Res Cardiol       Date:  2012-10-12       Impact factor: 5.460

3.  Hotline update of clinical trials and registries presented at the American College of Cardiology Congress 2010: ACCORD, INVEST, NAVIGATOR, RACE II, SORT OUT III, CSP-474, DOSE, ASPIRE and more.

Authors:  C Jacobshagen; D Westermann; C Holubarsch; M Böhm
Journal:  Clin Res Cardiol       Date:  2010-04-16       Impact factor: 5.460
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.